United States Patent 5,354,760: Tiagabine Crystalline Hydrochloride Monohydrate Patent Scope and Landscape

United States Patent 5,354,760 protected a specific crystalline hydrate of tiagabine hydrochloride, the active ingredient in Gabitril. The patent covered the solid form itself, analytical characteristics, aqueous crystallization processes, pharmaceutical compositions, and epilepsy-treatment methods. It issued on October 11, 1994 and has expired. The patent therefore creates no current U.S. exclusivity barrier to generic tiagabine, although its claim structure remains relevant to historical generic strategy, patent litigation analysis, and freedom-to-operate reviews involving legacy manufacturing records.

What drug and solid form does US 5,354,760 protect?

The patent protects crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate. This compound is tiagabine hydrochloride, commonly referred to as tiagabine.

The protected material has four defining attributes:

The R(-) stereochemical configuration.
The nipecotic acid active pharmaceutical ingredient.
The hydrochloride salt.
A crystalline monohydrate solid form.

The patent does not broadly claim all tiagabine, all tiagabine hydrochloride, or all physical forms of tiagabine. Its central product claims are directed to a particular crystalline form identified through thermal and spectroscopic characteristics.

Tiagabine is a gamma-aminobutyric acid, or GABA, reuptake inhibitor used for adjunctive treatment of partial seizures. The FDA approved Gabitril, tiagabine hydrochloride tablets, under NDA 020646 in 1997.[2]

What is the patent status and expiration date of US 5,354,760?

Item	Data
Patent	US 5,354,760
Subject	Crystalline tiagabine hydrochloride monohydrate
Assignee	Novo Nordisk A/S
Issue date	October 11, 1994
Patent regime	Pre-Uruguay Round Agreements Act patent
Applicable basic term	Generally 17 years from issue for qualifying pre-1995 patents
Expected expiration	October 11, 2011
Current status	Expired
Current blocking effect	None in the United States

Because the patent issued before the modern 20-year-from-earliest-effective-filing-date regime fully applied, its term was generally governed by the pre-URAA rule. The relevant patent term was approximately 17 years from issuance, producing an October 11, 2011 expiration date.[1]

The patent is therefore no longer enforceable against U.S. manufacture, sale, importation, or use. A later product or process that falls within the historical claims does not face present infringement liability based solely on US 5,354,760.

What does claim 1 cover?

Claim 1 covers the crystalline tiagabine hydrochloride monohydrate defined by a differential scanning calorimetry, or DSC, onset of approximately 80.8°C to 83.0°C.

The claim has a product-by-property structure. It does not identify the crystal solely by a conventional structural formula. Instead, it requires the chemical identity and a measurable thermal property.

Scope of the DSC limitation

A product would historically have been within claim 1 if it satisfied all of the following:

It was the R(-) enantiomer of the specified nipecotic acid derivative.
It was present as the hydrochloride salt.
It was crystalline.
It was a monohydrate.
Its DSC onset fell within approximately 80.8°C to 83.0°C.

The DSC limitation is important because a chemically identical compound can exist in different polymorphic, solvated, hydrated, or amorphous forms. The claim attempts to distinguish the patented crystal form from other tiagabine hydrochloride forms by thermal behavior.

The principal enforcement issue would have been analytical reproducibility. DSC onset can vary with:

Heating rate.
Sample mass.
Instrument calibration.
Atmospheric conditions.
Sample preparation.
Water content.
Purity and residual solvent.
Definition of “onset.”

A competitor could have disputed whether its material fell within the 80.8°C to 83.0°C range by challenging the testing protocol or the representativeness of the tested batch. The claim is narrower than a claim based solely on chemical composition, but potentially broader than a claim limited to a precise set of diffraction peaks.

What does claim 2 cover?

Claim 2 covers the same crystalline tiagabine hydrochloride monohydrate as defined by substantially the same X-ray diffractogram shown in Figure 1 and substantially the same KBr infrared spectrum shown in Figure 3.

This is a fingerprint-based product claim. It relies on two analytical profiles:

Powder X-ray diffraction, identifying the crystal lattice.
Infrared spectroscopy in potassium bromide, identifying molecular and solid-state characteristics.

Legal significance of “substantially the same”

The phrase “substantially the same” prevents the claim from being limited to laboratory data points reproduced with mathematical identity. It also creates a fact-intensive infringement inquiry.

Relevant comparison factors would include:

Peak positions.
Relative peak intensities.
Presence or absence of characteristic reflections.
Peak broadening.
Hydration state.
IR absorption bands.
Instrumental resolution.
Sample orientation and preparation.

An alternative crystal form with different characteristic X-ray reflections would generally present a stronger non-infringement position. An apparent match with shifted or altered peaks could raise both infringement and validity questions.

Claim 2 is technically complementary to claim 1. Claim 1 uses a thermal range. Claim 2 uses crystallographic and infrared identity. A batch could potentially satisfy one analytical definition more readily than the other, depending on testing conditions.

How broad are claims 3 and 4 for manufacturing?

Claims 3 and 4 cover processes for producing the patented crystalline hydrate. They are narrower than general manufacturing claims because both require an aqueous crystallization step.

Claim	Required process elements
3	Form an aqueous solution of tiagabine hydrochloride and crystallize the monohydrate by precipitation or recrystallization from water
4	Hydrolyze the ethyl ester of tiagabine hydrochloride under acid catalysis in aqueous solution, followed by precipitation or recrystallization of the monohydrate from that aqueous solution

Claim 3: aqueous precipitation or recrystallization

Claim 3 requires:

An aqueous solution containing tiagabine hydrochloride.
Formation of the crystalline monohydrate from that solution.
Precipitation or recrystallization from water.

The claim does not appear to require a particular acid, temperature, concentration, seeding protocol, cooling profile, or isolation technique. Its breadth is therefore concentrated in the general concept of obtaining the specific hydrate from an aqueous solution.

A process using a nonaqueous solvent system, a spray-drying route, a melt process, or direct conversion from an amorphous solid could have presented a design-around position, depending on whether water was still used as the crystallization medium.

Claim 4: ester hydrolysis followed by crystallization

Claim 4 adds a defined upstream chemical transformation. It requires acid-catalyzed hydrolysis of the ethyl ester of tiagabine hydrochloride in an aqueous solution, followed by crystallization of the hydrochloride monohydrate from the same aqueous solution.

This claim is more limited than claim 3 because it requires:

The ethyl ester starting material.
Acid-catalyzed hydrolysis.
An aqueous reaction environment.
Subsequent crystallization from the aqueous solution.

A process that hydrolyzes the ester in an organic solvent, uses base-catalyzed hydrolysis, isolates an intermediate before crystallization, or obtains a different solid form would have stronger non-infringement arguments.

What do claims 5 through 7 cover for pharmaceutical compositions?

Claims 5 through 7 cover pharmaceutical compositions containing the patented crystalline hydrate and a pharmaceutically acceptable carrier or diluent.

Claim	Scope
5	Composition containing an effective antiepileptic amount of the DSC-defined crystalline hydrate
6	Oral dosage unit containing 1 to 200 mg of the DSC-defined crystalline hydrate
7	Composition containing the X-ray/IR-defined crystalline hydrate

Claim 6 is the most commercially specific composition claim because it requires an oral dosage unit and a dose range of 1 to 200 mg.

The claim does not require a particular excipient, tablet coating, dissolution profile, release profile, or manufacturing method. It could therefore have reached conventional immediate-release tablets containing the claimed solid form.

The commercial relevance of claim 6 was significant during the branded-product period because Gabitril was marketed as oral tablets containing 2 mg, 4 mg, and 12 mg of tiagabine hydrochloride. Those strengths fall within the claimed 1 to 200 mg range.[2]

The claim would not necessarily reach:

A dosage form containing a different tiagabine polymorph.
An amorphous tiagabine hydrochloride formulation.
A formulation containing a different salt.
A product in which the active ingredient was chemically modified.
A formulation that did not contain the claimed crystalline monohydrate.

The product-by-formulation analysis would depend on whether the final dosage form retained the claimed crystal form. Milling, granulation, compression, drying, and storage can alter hydration and crystallinity. A patent analysis would therefore need to test both the incoming active ingredient and the finished dosage form.

What do claims 8 through 11 cover for epilepsy treatment?

Claims 8 through 11 are method-of-treatment claims directed to treating epilepsy in a mammal by administering the patented crystalline hydrate.

Claims 8 and 9 use the DSC-defined form. Claims 10 and 11 use the X-ray/IR-defined form.

The claims require:

A mammalian patient.
Epilepsy.
Administration of an effective amount.
The specified crystalline tiagabine hydrochloride monohydrate, either alone or in a pharmaceutical composition.

These claims are narrower than a broad method claim covering treatment with any tiagabine compound. They require administration of the particular solid form. In practice, the key historical issue would have been whether the dosage form administered to the patient contained the claimed crystalline hydrate.

After patent expiration, these method claims no longer create U.S. patent infringement risk. Their former presence could nevertheless have affected ANDA certification strategy because a generic applicant had to assess whether the listed patent claimed the drug substance, drug product, or method of use.

How many distinct claim categories does US 5,354,760 contain?

The patent contains four principal claim categories:

Product claims: claims 1 and 2.
Manufacturing-process claims: claims 3 and 4.
Pharmaceutical-composition claims: claims 5 through 7.
Method-of-treatment claims: claims 8 through 11.

The patent uses claim duplication to define the same solid form through alternative analytical techniques. Claims 1, 5, 6, 8, and 9 use the DSC range. Claims 2, 7, 10, and 11 use the X-ray and IR profiles.

This structure is commercially practical. A product claim can reach the active ingredient itself. Process claims target manufacturing. Composition claims target finished dosage forms. Method claims target therapeutic use.

What patents preceded or surrounded the tiagabine crystalline-form patent?

The broader tiagabine patent estate included earlier composition-of-matter and therapeutic patents. The most important earlier U.S. patent associated with tiagabine is US 5,010,090, which covered N-substituted nipecotic acid derivatives, including tiagabine-related chemistry.[3]

Patent	General subject	Strategic role
US 5,010,090	N-substituted nipecotic acid derivatives	Earlier compound and therapeutic protection
US 5,354,760	Crystalline tiagabine hydrochloride monohydrate	Solid form, manufacturing, formulation, and treatment protection
FDA-listed Gabitril patents	Drug substance, product, or use claims	Historical Hatch-Waxman exclusivity analysis

The earlier compound patent had an earlier expiration date than US 5,354,760. This created a typical lifecycle pattern: the basic compound patent expired first, while the later crystalline-form patent potentially extended exclusivity for products containing the specific solid form.

A generic manufacturer could, in principle, have pursued one of several strategies:

Challenge validity or infringement of the crystalline-form patent.
Use a non-infringing solid form.
Use a process that avoided the claimed aqueous crystallization steps.
Wait for patent expiration.
File a Paragraph IV certification against a listed patent.

What was the Orange Book status of tiagabine?

Gabitril was an FDA-approved tiagabine hydrochloride tablet product under NDA 020646. The Orange Book historically listed patent information associated with the product, including solid-form protection relevant to US 5,354,760.[2,4]

The practical Orange Book consequences were:

A listed patent could delay approval of an ANDA following a Paragraph IV certification if the NDA holder or patent owner filed suit within the statutory period.
A Paragraph III certification could defer approval until patent expiration.
A Section viii statement could omit a patented method of use where the proposed label did not include that use.
Once the patent expired, US 5,354,760 ceased to create a patent-based ANDA approval block.

The patent’s claims were unusually distributed across product, process, composition, and method categories. For a generic applicant, the principal certification question would have been whether the proposed active ingredient and finished tablets contained the claimed crystalline hydrate.

When did tiagabine lose exclusivity?

Tiagabine lost exclusivity in stages rather than on a single date.

Exclusivity layer	Approximate end
Earlier compound patent protection	Approximately 2008 for the principal early U.S. compound patent
US 5,354,760 crystalline-form patent	October 11, 2011
FDA small-molecule exclusivity	Expired long before the current period
Current US 5,354,760 protection	None

The small-molecule drug does not receive biosimilar exclusivity treatment. Tiagabine is regulated through the generic-drug pathway, principally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Were there Paragraph IV challenges or litigation involving US 5,354,760?

The patent could have been challenged through Paragraph IV certification during its term. A Paragraph IV certification would allege that the patent was invalid, unenforceable, or not infringed.

The current commercial consequence is limited because the patent expired in 2011. A new ANDA applicant no longer needs to overcome this patent as an unexpired Orange Book barrier.

A patent-specific litigation review should distinguish among:

ANDA litigation filed before expiration.
Declaratory-judgment actions.
Patent-office validity challenges.
Settlement agreements.
Product liability or regulatory disputes unrelated to patent validity.

The supplied claim set does not establish the existence, outcome, or parties to a particular Paragraph IV action or settlement. The reliable legal conclusion is that no present launch injunction or 30-month stay can arise from an expired US 5,354,760 patent.

Does US 5,354,760 create biosimilar risk?

No. Biosimilar analysis is not applicable to tiagabine hydrochloride because tiagabine is a chemically synthesized small molecule, not a biological product.

The relevant competitive pathway is generic substitution through ANDAs. Key regulatory issues include:

Pharmaceutical equivalence.
Bioequivalence.
Same active ingredient.
Same dosage form and strength.
Label conformity.
Controlled-substance status, if applicable.
Manufacturing and analytical controls for the active solid form.

The solid-form claims could historically have affected generic development even without biosimilar litigation. A generic applicant would need to characterize the API using DSC, X-ray diffraction, IR, water content, and related solid-state methods.

How strong was the patent estate?

Strengths

The patent had several enforcement advantages during its term:

It claimed the commercial crystalline hydrate directly.
It used multiple analytical definitions.
It included manufacturing claims.
It covered pharmaceutical compositions.
It included treatment claims.
The claimed dosage range covered commercial tablet strengths.
The patented form was linked to the marketed drug product.

Vulnerabilities

The estate also had material limitations:

The product claims were restricted to one crystalline hydrate.
DSC onset ranges can be sensitive to test conditions.
“Substantially the same” analytical-profile language can generate claim-construction disputes.
Process claims required aqueous crystallization.
Claim 4 required a particular ester-hydrolysis route.
Method claims depended on administration of the claimed solid form.
The patent was vulnerable to expiration-based design-around and launch strategies.
A later-form patent cannot extend protection over unclaimed alternative polymorphs or salts.

Overall, US 5,354,760 was a focused solid-state patent with meaningful historical commercial value but limited present-day leverage. Its strongest historical position was against products using the same crystalline tiagabine hydrochloride monohydrate in conventional oral tablets.

What generic launch scenarios existed?

During the patent term, generic entrants had four principal scenarios.

Scenario 1: Paragraph III certification

The applicant could accept the patent and defer approval until expiration. For US 5,354,760, that date was approximately October 11, 2011.

Scenario 2: Paragraph IV certification

The applicant could allege invalidity, unenforceability, or non-infringement. Litigation risk would have centered on:

Whether the generic API had the claimed crystal form.
Whether DSC results fell within the claimed range.
Whether X-ray and IR profiles were substantially the same.
Whether the manufacturing process used aqueous crystallization.
Whether the composition contained the claimed hydrate.

Scenario 3: Solid-form design-around

A generic manufacturer could seek a different polymorph, solvate, hydrate state, amorphous form, or salt. This strategy would require robust analytical evidence showing that the alternative did not meet the product claims.

Scenario 4: Process design-around

A manufacturer could use a route that did not include the required aqueous precipitation or recrystallization steps. This strategy would not avoid product claims if the final material nevertheless converted into the claimed crystalline hydrate.

What manufacturing and IP barriers remain today?

The patent barrier has ended, but technical barriers remain. Tiagabine hydrochloride manufacturing requires control of:

Enantiomeric purity.
Hydrochloride salt formation.
Hydration state.
Polymorphic form.
Residual solvents.
Particle size.
Moisture exposure.
Conversion during granulation and tableting.
Long-term solid-state stability.

A company developing a generic product should treat the crystalline form as a quality-by-design issue even though US 5,354,760 is expired. The commercial product may have used the patented hydrate, and regulators may expect control of the API’s identity and physical properties. Regulatory specifications do not recreate patent rights, but they can make a solid-form change operationally costly.

How does US 5,354,760 compare with a compound patent?

Issue	Compound patent	US 5,354,760
Protected subject	Chemical genus or active compound	Specific crystalline hydrate
Breadth	Generally broader chemical scope	Narrower solid-state scope
Design-around	Difficult if compound itself is required	Possible through alternative forms or processes
Product relevance	Covers active molecule	Covers particular API form
Process relevance	May cover synthesis	Covers aqueous crystallization routes
Commercial life	Earlier expiration	Later lifecycle protection
Current status	Expired	Expired

The crystalline-form patent was a classic secondary patent. It could extend commercial protection beyond the principal compound patent, but only for products and processes involving the specified solid form.

Key Takeaways

US 5,354,760 covers crystalline R(-)-tiagabine hydrochloride monohydrate.
Claims 1 and 2 define the product through DSC, X-ray diffraction, and IR characteristics.
Claims 3 and 4 cover aqueous crystallization and a specific acid-catalyzed ester-hydrolysis route.
Claims 5 through 7 cover pharmaceutical compositions, including oral dosage units containing 1 to 200 mg.
Claims 8 through 11 cover epilepsy-treatment methods using the claimed crystalline form.
The patent issued October 11, 1994 and expired approximately October 11, 2011.
It no longer blocks U.S. generic tiagabine approval or launch.
Tiagabine is a small molecule, so biosimilar analysis does not apply.
Historical Paragraph IV issues would have focused on solid-form identity, analytical testing, process steps, and claim validity.
The remaining barrier is technical and regulatory control of the API, not enforceable patent exclusivity.

FAQs

What is the active ingredient protected by US 5,354,760?

The active ingredient is tiagabine hydrochloride, specifically its R(-) enantiomer in a crystalline monohydrate form.

Does US 5,354,760 cover all tiagabine polymorphs?

No. The claims are directed to a defined crystalline tiagabine hydrochloride monohydrate identified by DSC, X-ray diffraction, and IR characteristics.

Could an amorphous tiagabine hydrochloride product infringe US 5,354,760?

During the patent term, an amorphous product would have had a stronger non-infringement position against the crystalline product claims, but the complete product and process facts would have controlled. The patent is now expired.

Is tiagabine hydrochloride subject to biosimilar approval?

No. Tiagabine hydrochloride is a chemically synthesized small molecule regulated through the generic-drug pathway, not the biosimilar pathway.

What is the current patent risk for a U.S. tiagabine generic?

US 5,354,760 creates no current patent infringement risk because it expired. Current risk would arise from other unexpired patents, regulatory requirements, manufacturing controls, or formulation-specific rights, not from this patent.

References

United States Patent and Trademark Office. (1994). Crystalline R(-)-N-(4,4-di(3-methylthien-2-yl)-but-3-enyl)nipecotic acid hydrochloride monohydrate, U.S. Patent No. 5,354,760.
U.S. Food and Drug Administration. (1997). Gabitril (tiagabine hydrochloride) tablets prescribing information. NDA 020646.
United States Patent and Trademark Office. (1991). N-substituted nipecotic acid derivatives, U.S. Patent No. 5,010,090.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	0582/91	Apr 02, 1991

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	180781	⤷ Start Trial
Australia	1641592	⤷ Start Trial
Australia	661483	⤷ Start Trial
Canada	2107223	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 5,354,760